Characteristic features of malignant lymphoma with central nervous system involvement.
BACKGROUND
Cerebral lymphoma is becoming increasingly common.


METHODS
We reviewed the records of all our patients with non-Hodgkin's lymphoma (NHL) seen from April 1987 to August 1996 in our institute. Our analysis of these patients with lymphomatous central nervous system (CNS) involvement documents the clinical features, histology, and prognostic factors in CNS lymphoma.


RESULTS
A total of 351 cases of NHL were treated in our institute. CNS lymphoma was found in 58 of 351 (16.5%) patients in our series. Forty-nine of 58 (84.5%) patients with CNS involvement also had systemic disease. Primary CNS lymphomas were detected in nine patients. Leptomeningeal infiltration was seen in 31 of 58 patients, whereas intracerebral infiltration was detected in 28 patients. Initial symptoms of CNS involvement included severe headache, muscle weakness, and other neurological signs. Malignant cells were detected in 32 of 132 studies in the cerebrospinal fluid examination. In the nine patients with primary CNS lymphoma, the median survival time was 16.5 months (range, 4-28 months). The overall median survival of the 58 CNS lymphoma patients was only 13.4 months (range, 1 to 32 months).


CONCLUSIONS
Because prophylactic treatment was only successful in systemically well-controlled patients, control of systemic lymphoma seems to be of great importance.
Yoshida
S
S
Department of Neurosurgery, Niigata Cancer Hospital, Japan.
Morii
K
K
Watanabe
M
M
Saito
T
T
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis; D016543:Central Nervous System Neoplasms / Q000134:cerebrospinal fluid / Q000150:complications / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000134:cerebrospinal fluid / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome